Abstract | Drug metabolism can produce metabolites with physicochemical and pharmacological properties that differ substantially from those of the parent drug, and consequently has important implications for both drug safety and efficacy. To reduce the risk of costly clinical-stage attrition due to the metabolic characteristics of drug candidates, there is a need for efficient and reliable ways to predict drug metabolism in vitro, in silico and in vivo. In this Perspective, we provide an overview of the state of the art of experimental and computational approaches for investigating drug metabolism. We highlight the scope and limitations of these methods, and indicate strategies to harvest the synergies that result from combining measurement and prediction of drug metabolism.
Metabolism is a signature of living systems, and enables organisms to create a viable environment within which to perform the complex biochemical transformations that maintain homeostasis. The metabolic sys tem has evolved as the main line of defence against foreign, hazardous substances, by transforming them into readily excretable metabolites. These xenobiotics include synthetic drugs, in addition to naturally occurring substances (such as bacterial, fungal and herbal toxins), which are often produced as part of a specific defence mecha nism. Recent studies have also highlighted the often synergistic signalling -which is facilitated by metabolism -between the host organism and the microbiome 1 .
For about 75% of all drugs, metabolism is one of the major clearance pathways 2, 3 . The process of biotransformation can produce metabolites with substantially altered physicochemical, physiological, pharmaco logical, and toxicological profiles [4] [5] [6] . Metabolism is the main factor mediating the activation, deactivation, toxification and detoxification of small molecules, and is a key determinant in the performance and safety of small molecules, including their uses in medicines, cosmetics, nutritional supplements and agrochemicals
.
Metabolic systems are highly complex and adaptable. A plethora of diverse enzyme families are involved in xenobiotic metabolism, including cytochrome P450 (CYP) enzymes, dehydrogenases, flavin containing monooxygenases, hydrolases, peroxidases, UDPglucuronosyltransferases (UGTs), sulfotransferases, and glutathione Stransferases 7 . Their expression patterns and substrate specificities can vary greatly among different species, which implies that there is a risk of missing toxic metabolites that are formed in humans when extrapolating from in vitro and animal testing results. Expression patterns also differ between tissues and organs, and there are indications that metabolic enzymes engage in syner gistic collaborations with transporters (for example, CYP3A4 and Pglycoprotein) 8, 9 . Moreover, many inter and intraindividual factors need to be considered, such as gender differences and genetic polymorphisms, age, biological rhythms, pregnancy, intestinal flora, diseases, stress, lifestyle, diet and medication 4 . Hence, even with the advanced technologies and knowledge available today, accurate prediction of drug metabolism remains highly challenging.
Understanding metabolic processes at the molecular level is of fundamental impor tance for successful drug discovery and development. Knowing the metabolic prop erties of a molecule can help to optimize the stability -and consequently the in vivo halflife and risk-benefit ratio -of a drug. A plethora of experimental methods are available for investigating the metabolic fate of drugs at an unprecedented level of detail. However, these experimental approaches remain demanding with respect to scientific equipment, human expertise, cost and time. Consequently, there has been substantial interest in the development of computa tional tools to predict drug metabolism, which potentially have higher throughput at a lower cost than existing tools, facilitating their application to large libraries of com pounds early in the drug discovery process. In silico methods allow the prediction of the metabolic fate of virtual compounds and enable planning for the most promising strategy to optimize the metabolic stability of project compounds a priori.
However, experimental and theoretical approaches to investigating drug metabolism are (still) all too often regarded as separate domains. It is crucial to realize that there is enormous potential for synergy in the com bination of both areas, which will allow the analysis and prediction of drug metabolism to make a major leap forward. Here, we first summarize the state of the art in biosystems and analytical methods for investigating drug metabolism. We then consider compu tational approaches, and finally discuss the opportunities that could be realized through greater integration of experimental and computational approaches.
Biosystems and analytical methods
CYPs have a key role in drug metabolism, and the most relevant forms are expressed predominantly in the liver, but also in a variety of other organs at lower levels (FIG. 1) . Hence, liver (or liverderived) in vitro systems are often the most convenient, interesting and important experimental model systems for metabolism studies -for example, when considering the firstpass metabolism of an orally bioavailable drug.
It is essential and valuable to use in vitro systems with humanderived material early in drug discovery in order to more accurately predict metabolism in humans, because of the considerable variability in metabolism among different species. Several in vitro systems, as well as new in vivo approaches, are available and can be specifically used depending on the issue or problem to be solved (TABLE 1) . The simplest systems are recombinant enzymes (which are expressed and used together with coenzymes to achieve optimal catalytic activity). For example, single CYP isoforms can be used to assess which isoforms are involved in the metabolism of a compound or for drug interaction studies. From native material (derived, for example, from the liver), different enzyme families can be separated by centrifugation. Soluble cytosolic enzymes such as sulfotransferases (SULTs) remain in the supernatant, whereas membranebound enzymes such as CYPs and UGTs are enriched in the pellet; after resuspension, 'microsomes' (membrane vesicles of the endoplasmic reticulum) are obtained. Microsomal preparations can be stored easily while retaining their function ality, and are convenient to use because they are also available in sufficient quantity for highthroughput assays.
Box 1 | The many implications of drug metabolism
Categories of drugs with respect to their metabolic behaviour 'Soft drugs' have -or are designed for -a fast and predictable metabolic transformation into inactive, non-toxic metabolites (often via conjugation or hydrolysis reactions) 106 . Examples include succinylcholine and esmolol. Metabolically stable (or highly resistant) drugs, however, are excreted without undergoing metabolism. Examples include lisinopril and bisphosphonates.
Drugs with active or highly active metabolites include cisplatin (which is metabolized to monoaqua and diaqua species), diazepam (which is metabolized to nordiazepam), encainide (which is metabolized to O-desmethylencainide and 3-methoxy-O-desmethyl encainide), morphine (which is metabolized to morphine-6-O-glucuronide), tamoxifen (which is metabolized to 4-hydroxytamoxifen and endoxifen), and tramadol (which is metabolized to O-desmethyltramadol).
Metabolites that have comparable or improved therapeutic properties and are marketed as drugs include oxazepam (which is a metabolite of diazepam), cetirizine (which is a metabolite of hydroxyzine), desloratadine (which a metabolite of loratadine), paracetamol (which is a metabolite of phenacetin), and fexofenadine (which is a metabolite of terfenadine).
Prodrugs are medicinal compounds whose complete or near-complete therapeutic potential is based on the activity of the metabolite (or metabolites) [107] [108] [109] [110] [111] . Chemical groups that are liable to metabolism are often introduced to improve ADME (absorption, distribution, metabolism and excretion) properties or to reduce toxicity (for example, chemotherapeutics). Examples include enalapril (which is metabolized to enalaprilat), fenofibrate (which is metabolized to fenofibric acid), levodopa (which is metabolized to dopamine), oseltamivir (which is metabolized to oseltamivir carboxylate) and valaciclovir (which is metabolized to aciclovir).
Changes in pharmacological activity
Drug metabolites can range from intrinsically inactive to highly active compounds, on the same pharmacological target as the parent drug or any other biomolecule 4, [112] [113] [114] . Metabolism can produce active species that contribute to the therapeutic activity of drugs, and this actually is not a rare event.
In the past, drugs were often developed and almost solely guided by animal models, and often the observed biological response was significantly (or even completely) due to an active metabolite and not the parent drug 113 . Gain of therapeutic activity may be observed for metabolites with favourable physicochemical properties for disposition, assisting transfer to their pharmacological target. Chiral inversion as a result of metabolism may also lead to substantial changes in biological activity and/or toxicity. Metabolites may be the preferred substrates of influx transporters.
Conversely, extensive biotransformation of metabolically unstable molecules into inactive or rapidly excreted metabolites can result in a substantial decrease in, or complete loss of, therapeutic efficacy. This is, in principle, predictable and assays are available that can identify problematic molecules. Metabolic instability is particularly challenging if drug metabolism is induced as part of a resistance mechanism (which is most commonly observed for anti-infectives and anticancer drugs). Metabolites may also be substrates of efflux transporters.
Toxicity due to metabolism
Biotransformation can result in adverse drug reactions (ADRs) 4 . On-target ADRs (in the context of metabolism) are a result of exceedingly high concentrations of a drug or an active metabolite, sometimes in a non-target tissue. They are generally dose-dependent and, in principle, predictable.
Off-target ADRs result from the interaction of a drug or its metabolite (or metabolites) with a non-intended target. A relevant example is the cardiotoxicity caused by several (often but not exclusively) lipophilic drugs belonging to various pharmacological classes by blocking the human ERG potassium channel at therapeutic doses 115 . Off-target ADRs are generally dose-dependent and, in principle, predictable.
ADRs involving reactive metabolites are a cause for concern because they can involve covalent binding to biomolecules (adduct formation) and/or oxidative stress following the formation of reactive oxygen species 116, 117 . They are, in principle, predictable (or rationalizable) and dose-dependent.
Idiosyncratic drug reactions are rare (<1 case in 5,000) but with potentially severe consequences (anaphylaxis, blood dyscrasias, hepatotoxicity, and skin reactions). They are not currently predictable and apparently dose-independent. Their underlying mechanisms are poorly understood but are often thought to be associated with reactive metabolites 118 .
Drug-drug interactions
A drug-drug interaction refers to the situation where the drug concentration present at target (or anti-target) sites is changed dramatically by the interference of another substance with drug-metabolizing enzymes or related biomolecules. Potential outcomes of drug-drug interactions are as follows: loss of pharmacological efficacy owing to enhanced clearance; toxic effects caused by accumulation of the drug or its metabolites; and increased rate of reactive, toxic intermediates formed. Drug-drug interactions can be life-threatening. For example, monoamine oxidase inhibitors are well known for potentially lethal dietary 119 and drug 120, 121 interactions, and hence they are currently used only as a last resort for the treatment of atypical depression.
Drug resistance
Induction of metabolic pathways is a major route of drug resistance, in particular for anti-infectives and cancer drugs, but this also has huge implications for the effectiveness of pesticides. Multidrug resistance can be driven by active efflux facilitated by transporters 122 .
Changes in physicochemical properties
Biotransformation has an impact on the physicochemical properties of drugs 6 and hence their pharmacokinetics, in particular with respect to distribution and excretion. It also affects parameters such as absorption, passive membrane permeation, transport and binding to macromolecules 9, 12 . Another subcellular matrix is the S9 fraction, which consists of both the cytosolic and microsomal fractions. In all subcellular fractions, owing to dilution or washout of cofactors during the preparation process, cofactordependent enzymes in microsomes such as CYPs or UGTs need to be specifically supplemented with the cofactor (NADPH in the case of CYPs) to regain enzymatic activity. The metabolically most competent system is one that has intact liver cells (hepatocytes), and in which all appropriate cofactors and coenzymes are present. Hepatocytes, although less 'robust' than microsomes, are useful when a more comprehensive picture of the hepatic metabolism of a selected compound is required. Both fresh and commercially produced cryopreserved primary hepato cytes, as well as immortalized hepatocyte derived cell lines, can be easily produced from preclinical species, and there is now more straightforward access to humanderived material. New preclinical models such as 'humanized mice' (either mice with specific human drugmetabolizing genes inserted 10 or chimeric animals wherein human hepato cytes have replaced >90% of the murine hepatocytes in the liver) 11 are becoming avail able, which may improve studies of human metabolism and drug-drug interactions in an in vivo animal model very early in the drug discovery and development process, before candidates enter clinical studies 12, 13 . At present, highperformance liquid chromatography (HPLC) separation systems coupled to mass spectrometers (MSs) Note that CYP2 and CYP3 families have evolved as essentially xenobiotic metabolizing enzymes, whereas CYP11 and CYP46 are two of the many CYP families that have essential physiological roles. Colour intensity indicates the local buriedness (a dark colour indicates that the active site is far from the protein surface; a light colour indicates that the active site is exposed). PDB ID, RCSB Protein Data Bank identifier.
comprise the workhorse for detecting and characterizing drug metabolites. The metabolite data generated by LC-MS analyses are in general qualitative in the absence of synthetic reference material, as the parent drug and the metabolites formed can have dramatically different responses to MS. Integrating ultraviolet detectors in these systems can provide at least semiquantitative data, provided that metabolism does not affect the chromophore in the parent drug, and this can be used to assess major or minor metabolic pathways. Without synthetic standards (ideally, stable isotope labelled, if LC-MS is to be used for quanti fication), quantitative data -particularly from complex in vivo matrices -can only be generated using radiolabelled com pounds, and these (like the synthetic standards of the metabolites themselves) are rarely available during the discovery phase.
Depending on the spectrometer used -with highresolution mass spectrometry (HRMS) being the preferred optiona suite of MSbased experiments can be used to help characterize metabolites, such as MS/MS, MS n , MS E , mass defect filters (MDFs) and neutral losses 14, 15 . The expe rienced MS operator can use a variety of strategies, including knowledge, rules and databases 16 , for metabolite detection and identification (MetID) to deduce lists of masses to be monitored. Indeed, all of the major mass spectrometer manufacturers offer bespoke metabolite identification soft ware for this purpose. This can be supple mented by in silico tools such as IsoScore 17 or MassMetaSite 18, 19 , which predict the metabolic fate to guide metabolite detec tion and identification 20 . The expert system Meteor Nexus 21 includes functionality for linking MS data to metabolites predicted for phase I and II biotransformations. It highlights matches in the graphical depic tion of the metabolic tree. Tools based on the SyGMa 22 metabolite prediction method have also been successful in supporting MetID efforts for drugs 23 , and recently an open source library for LC-MS data processing, MassCascade 24 , has been released. Another method is to search for metabo lites using multivariate statistical analysis of the data (this approach is derived from the developing field of metabonomics, in which data are used to deduce the relationships between the metabolism and phenotypic readouts such as clinical end points) 25 .
Comparison of the MS data from a sufficient number of samples obtained from dosed and control in vitro incubations, or animal experiments, can be mined using techniques such as principal components analysis for changes in metabolic profiles. Although some of these changes may well result from alterations in the endogenous metabolites, other changes will be due to the production of drug metabolites 26, 27 . Despite the availability of these MS technologies, and the various in silico aids, it is often difficult, or impossible, to assign a full constitutional structure. The use of techniques such as LC-NMR spectroscopy may enable a more complete structural characterization of unknown metabolites, provided sufficient material is available 28 . However, full metabolite characterization is generally undertaken only on a 'for cause' basis, or after a compound has entered full development 14 . In the initial stages of dis covery programmes, a simple measure of compound stability (that is, rate of substrate disappearance) in hepatic microsomes or primary hepatocytes may suffice. Based on the data generated here, those molecules with greater metabolic stability can then be chosen for further investigation and chemi cal optimization. This type of analysis can easily be automated, and medium to high throughput metabolic stability assays are routinely applied [29] [30] [31] . Such assays can also be applied to investigations of a compound's susceptibility to metabolism by specific enzyme systems.
Once appropriate structures have been selected for lead optimization, additional metabolic information helps to identify meta bolic 'hotspots' , so that in vivo break down can be restricted and exposure improved. Rapid generic analysis based on a reversedphase gradient chromatographic separation may be used for metabolite pro filing. Such methods can indicate the general nature of the biotransformations occurring (hydroxylation, dealkylation, reduction, con jugation reactions, and so on) and provide insights into the sites of metabolism, as well as the enzyme classes involved. Microsomal systems are also useful for examining candidates for the generation of reactive intermediates based on socalled 'trapping' experiments 32, 33 . Such screening aims to • Determination of hepatic metabolite profiles, including conjugations and reactive metabolite trapping, and metabolic stability
Specific reactive metabolite trapping in microsomal incubations (trapping of soft nucleophiles using, for example, glutathione or cysteine, and trapping of hard nucleophiles with, for example, cyanide)
• Identification of hot spots leading to reactive intermediates, using high-resolution MS or, in complicated cases, NMR for precise structures Animal models: most commonly rodents (mice and rats), including complex models designed to look at, for example, biliary elimination. Newer models include genetically modified and 'humanized' strains (usually mice) as well as 'chimeric' animals containing, for example, human hepatocytes
• Used to solve problems in which, for example, in vivo pharmacokinetics are poorly predicted by in vitro studies, for example, owing to unchanged excretion, drug-drug interactions or when more information on compound distribution is needed CYP, cytochrome P450; LC, liquid chromatography; MS, mass spectrometry, NMR, nuclear magnetic resonance; UDPGA, uridine diphosphate glucuronic acid; UGT, UDP-glucuronosyltransferase.
detect both 'soft' and 'hard' nucleophiles formed as reactive metabolites via panels of trapping reagents. As programmes progress through the discovery phases, studies of more complex systems such as hepatocytes will be used, giving a more complete picture of hepatic metabolism, including further information about the generation of reactive intermedi ates. Finally, keeping in mind potential issues with allometric scaling, studies in animals provide the opportunity to investigate the in vivo metabolism, distribution and excre tion of a selected number of candidate com pounds, often using a much more bespoke chromatographic separation to maximize the data recovery from samples such as urine, bile and tissue extracts. However, the difficulties of obtaining truly comprehensive metabolite profiles in the absence of radio labelled materials (or some other tracer) in biofluids should not be underestimated. The presence of endogenous metabolites increases the complexity of detection, whereas effects such as ion suppression may attenuate signals for candidate drug metabolites.
Computational approaches
A wide array of computational methods and integrated approaches have been developed for the prediction of drug metabolism, and are distributed in the form of web services and as free or commercial software 34, 35 (TABLE 2). They may be classified as specific (local) or comprehensive (global) tools 36, 37 . Specific models apply to certain biomolecules (mainly metabolic enzymes) and/or to specific metabolic reactions, whereas global models are, in principle, applicable to diverse biological systems (that is, to any metabolic enzyme and biotransformation) and to most small organic compounds. The goal of many metabolism software packages generally lies in combining various tools and methods not for a single enzyme, but for the largest possible number of targets related to drug metabo lism. The inclusion of other functional pro teins that may synergize with metabolizing enzymes, such as transporters (for example, the drug transporter Pglycoprotein) 9 , can also be envisaged.
Among the most common applications of computational methods is the determina tion of fundamental structural, functional and mechanistic properties of biomolecules that are related to drug metabolism, which enables the identification of metabolically labile positions -sites of metabolism -in small organic molecules and the prediction of metabolites. Once the chemical structures of the actual metabolites are determined, a good starting position for predicting their reactivity, toxicity, bioactivity and other pharmacokinetic and pharmacodynamic (PK/PD) properties has been obtained. An overview of the scope and limitations of computational methods is provided in Many computational chemistry techniques have been adopted for the task of drug metabolism prediction, but it has become clear that the key to success is the integration of various methods and resources. Below, we discuss the components that are needed.
Component 1: experimental data.
Computational models are often (but not exclusively) based on experimental data, and the amount and quality of the avail able data will determine the coverage and performance of the model. Experimental data are generally generated under con trolled conditions, meaning that a number of variables are set and kept constant, leaving large portions of the 'space' of possibilities unexplored. As an example, the concentra tions and distributions of metabolic enzymes in vivo may not be equivalent to those from which the experimental model was derived. Computational models can therefore be false, irrelevant or, at best, incomplete.
Recently, efforts in making experimental data on small organic molecules available to the public have increased 38 , but data on drug metabolism are still sparse. There are only a few databases of relevance to this topic in the public domain 35 (TABLE 4) , and even proprietary data collections are surprisingly limited in their coverage. Data collections on metabolism have been built up over decades and are often not stored in a machinereadable format.
Assay technologies, protocols, require ments for new medicines, definitions of targets and the chemical space of interest have changed over time, resulting in hetero geneous data sets. Apart from the limited quantity and coverage, data quality is an additional concern, including issues related to experimental variability and errors intro duced during data collection, curation and manipulation 37, 39, 40 . When searching the literature (or inhouse archives) for meta bolic data, one is all too often confronted with unconvincingly documented or unsolved constitutional assignments, espe cially for minor metabolites. For example, sites of hydroxylation or conjugation (that is, product regioselectivity) are often left unassigned. Such partly solved metabolic structures certainly have some utility, but they must be clearly designated as such to avoid over or misuse. Configurational (that is, stereochemical) aspects of metabo lite formation and characterization have received considerably less attention than constitutional aspects 41, 42 , despite their obvi ous pharmacological significance. For all these reasons, distilling highquality data that can be used for training computational models is a challenging and labourintensive task that needs to be done by experts.
Experimental data such as bioactivities can be modelled using quantitative struc ture-activity relationship (QSAR) tech niques. These methods have evolved from univariate statistical approaches to multi variate machine learning techniques based on heuristics. Classical QSAR methods apply linear regression techniques to fit experi mental data. Regression (numerical) models have historically been used to model contin uous responses (such as the octanol-water partition coefficient logP) from highquality data sets, whereas classification (categori cal) models are often favoured for modelling noisy data (for example, data collected from different laboratories or from assays with a high intrinsic variability). Machinelearning methods generally outperform statistical approaches on large and highly diverse data sets featuring complex nonlinear relation ships. With the rapid increase in available data, these methods are becoming increas ingly popular, despite obvious drawbacks such as limited interpretability 37 . However, it may be unwise to dismiss such models for the sole reason of lack of (linear) inter pretability. Here, chemists can learn from other disciplines -such as physics and engineering -that use nonlinear modelling approaches successfully for solving complex problems.
QSAR models have primarily been reported for the interaction of molecules with specific CYP isoforms, as well as UGTs and sulfotransferases, and receptors involved in enzyme induction, in particular the CYPinducing aryl hydrocarbon receptor (AHR), constitutive androstane receptor (CAR), and pregnane X receptor (PXR) 37, 43, 44 . On a broader scale, statistical and machine learning methods are used to predict com prehensive bioactivity spectra of small molecules. However, current mechanistic models generally do not describe how metabolism is linked to downstream path ways, and hence are limited in their ability to predict phenotypes 45 . Linking pathway infor mation to targets can hence improve model accuracy. MetaCore and MetaDrug 46, 47 , two pharmacology platforms that use comprehensive biological networks for estimating the pharmacological effects and risk of small molecules, harness this approach. However, the coverage and accu racy of annotated pathways is still a work in progress and there is often less overlap between different databases of annotated pathways than one would expect. This is often compounded by the lack of informa tion on tissue expression levels and rate constants for metabolizing enzymes. There is clearly an opportunity to invest addi tional efforts in this area to further increase the reliability of computational models. The majority of toxicity models available to date are trained solely on toxicological end points. In general, these quantitative structure-toxicity relationships (QSTRs) make use of only a few basic chemical descriptors in combination with classic linear modelling techniques. They serve primarily as hazard identification tools to support general risk assessment. Only rarely are they derived for exposure-response relationships that allow the prediction of absolute toxicity in isolation 39 . Biotransformation data can be used to derive models for predicting both the sites and products of metabolism in an automated fashion. MetaPrint2D 48 , for example, gener ates simple statistical models to predict sites of metabolism from biotransformation databases. An extension of this software, MetaPrint2DReact 48 , identifies and encodes the type of metabolic reaction observed for specific atom environments. The program is able to generate the chemical structures of likely metabolites by applying reaction rules to predicted sites of metabolism. Realistically, such data mining approaches require thousands of biotransformation records for proper model development, which -with the present sparsity of data -is one of their major limitations. These methods therefore have limited applicability.
Component 2: expert knowledge.
Given the limited quality and quantity of available data, and the wealth of empirical knowledge that medicinal chemists have accumulated over decades of research in drug metabolism, scientists have been keen to devise sets of rules (dictionaries) from expert human knowledge, and to develop reasoning engines to apply this knowledge to metabolite structure prediction 49 . Knowledgebased approaches such as Meteor 21 predict the sites and products of metabolism by scrutinizing a molecule of interest for the presence of target fragments. Their key advantage is the provision of a rational basis underlying a prediction (for example, literature references and brief descriptions). However, these tools often generate a combinatorial explosion of predictions, as all possible combinations of transformations encoded by the dictionary can be performed for several (usually three) generations of metabolites. Without pruning of the product trees pro duced, large numbers of metabolites may be presented to the user, and their analysis requires experience and diligence. Hence, the ranking of metabolites and the defini tion of adequate cutoff criteria are key challenges of knowledgebased approaches, which require the integration of additional components into such expert systems.
Rulebased systems are also firmly established in predictive toxicology, in which they are used to interrogate molecules for structural elements linked to toxicity 50 . They have received considerable interest from regulatory authorities concerned with medicines registration (for example, see REF. 51 ) and are typically included as part of the guidance in investigating the toxic liability of new substances, including drugs. However, users should be aware that calculated physicochemical parameters are themselves often subject to notable error, which may result in the incorrect inclusion or elimination of predicted metabolites. The effects of transporters on the excretion of small molecules can also be profound. For example, glucose is almost 100% reabsorbed in the kidneys from the ultrafiltrate despite being very hydrophilic.
Component 4: structure of metabolic proteins.
Ligandbased methods consider only the substrate, and this will not include the complex interaction and dynamics between the ligand and the protein. Therefore, ligandbased methods are required to deal with uncertainty about the structure and dynamics of the macromolecular targets. Structurebased methods additionally take into account the structural properties of metabolic proteins, which are a key compo nent for understanding protein-ligand interactions at an atomic level of detail. Only 12 years ago, the first crystal structure of a human microsomal CYP (CYP2C9) was resolved 52 . Today, approximately 100 crystal structures of CYPs are available, covering most of the isoforms relevant to human drug metabolism. This is a respectable collection of potentially valuable data, but it is impor tant to note that these structural models cover only a fraction of the conformational space of enzymes that is relevant to the binding of small molecules 53 . Automated ligand docking can be useful in determining the most likely pose of the ligand in the binding site. Sites of metabolism can be predicted by relating the proximity of ligand atoms in a computed docking pose to the catalytic centre of the target enzyme. This approach is generally able to correctly predict the approximate ligand orientation within the binding pocket (for binding sites of low flexibility) and pro vide a structural hypothesis for the observed biological response [53] [54] [55] . The technique is particularly valuable for rationalizing, for example, diverging biological properties of enantiomers. In fact, we advocate that the prediction of metabolic stereoselectivity be added as a benchmark of the maturity of substrate-enzyme docking simulations. Current automated docking methods are reasonably efficient in determining the cor rect docking pose, but the scoring functions are not reliable in ranking ligand binding affinities 56 . Specifically, although enthalpic contributions to ligand-receptor binding for highaffinity molecules are more or less captured by the various scoring functions that guide the ligand docking process, the entropic contributions (and other more subtle effects such as changes in the heat capacity of the complex) elude these techniques. There are remarkable differences in the per formance of the various docking algorithms but the limitations of this method are pri marily defined by the ability to explore con formations of the ligand and binding site, the chosen protein conformation, expert knowledge of the target, the algorithm itself and model parameterization.
Steric and chemical properties of target metabolic proteins can be described by molecular interaction fields (MIFs). MIFs are generated by embedding the target into a grid and computing interaction energies with a chemical probe for each grid node 57, 58 . A probe is a small chemical fragment that is used to characterize specific types of chemi cal features, most commonly hydrophobic features and hydrogen bonding regions. MIFs can be visualized as isopotential 3D maps indicating the directionality and topology of the interactions formed between a ligand and the receptor. MetaSite 59 is such an integrated software package for metabolism prediction that is based on MIFs. Among several other components, it features a fast docking surro gate method to relate the structure of small molecules to CYPs for the prediction of sites of metabolism and metabolites. Similar con straints on protein flexibility and accuracy of the scoring functions apply.
Component 5: target flexibility. Metabolic enzymes and effectors involved in their regulation are known for their remarkable ligand promiscuity. The plasticity and size of their binding sites (some of them have two or more) are directly related to their function, which -in the case of xenobiotic metabolizing enzymes -is to provide a flex ible and adaptable system for processing a wide range of substrates. Today, molecular dynamics (MD) simulations, often in combi nation with quantum chemical methods, are the most powerful theoretical approaches for analysing and predicting the inter actions of protein-ligand pairs, and much of our knowledge about the structure, function, specificity and mechanisms of metabolic enzymes has been derived from these simulations 60, 61 . MD simulations have revealed confor mational changes that are induced by the binding of small molecules 62, 63 to various CYP isoforms and established a relationship between substrate specificity and enzyme malleability 64 . They have been used to study the solvation of the active sites of various CYP isoforms 65 , and the active site access and egress pathways, which might have a key role in substrate selectivity and specificity 66, 67 . Various methods have been developed to enhance conformational sampling, including the application of an artificial force to the ligand in order to pull it towards a specific direction (steered MD simulation) 68 or in a random direction (random accelerated MD simulation) 69 . The fact that the dynamic motions of CYPs are affected by their bind ing to membranes introduces another layer of complexity to their analysis 60 . Methods that are based on the calculation of freeenergy pathways such as freeenergy perturbation 70 , thermodynamic integration 71 and the Bennett acceptance ratio method 72 allow the calculation of the free energy of binding with a typical mean absolute error of ~1.5 kcal per mol 73 (note that the difference between a high and lowaffinity analogue is only a few kcal per mol). These methods also come at high computational cost. Faster freeenergybased methods (such as linear interaction energy; LIE) 74 have been devel oped, but they are generally less accurate 73 . Freeenergybased methods have been used, for example, to study the binding of the acidic and lactone forms of atorvastatin to CYP3A4 (REF. 75 ), the stereoselective metabo lism of CYP substrates, and the impact of mutations on substrate affinities 76, 77 . MD simulation methods come with con siderable demands in computational power and human expertise. Therefore, they have mostly been applied a posteriori for studying the timedependent structural and electronic properties of the most important metabolic enzymes. Graphics processing unit (GPU) technology with faster MD algorithms is boosting capabilities to sample the phase space more comprehensively 78 , but the set up of the simulation (protein preparation and ligand parameterization) in particular, and the respective analysis remain labori ous and accessible to experts only. Data can be complex, 'big' and overwhelming; there is, therefore, a need to develop more efficient ways to decode the crucial bits of information. Various clustering techniques can be applied to elucidate representative protein conformations that could be used for automated docking 79 . The many options to consider (water molecules, solvation, pro tonation and other factors) result in a very large number of possible receptor models. From a computational point of view, this is generally not a limitation as molecules can be easily docked against thousands of pro tein structures within a short period of time. The problem lies again with the insufficient performance of scoring functions, leaving the question of which docking pose to trust. Component 6: substrate reactivity. The reac tivity of a smallmolecule substrate is the major determinant of metabolism (at least for CYPmediated biotransformations) 80 , and quantum mechanical (QM) methods, as they simulate the electronic structure of the system, allow accurate investigation of reactivity. Regarding metabolism as a hypo thetical twostep process, the molecule must first fit into the active site, and then it must be sufficiently activated by the enzyme to undergo metabolism. QM systems generally take into account only the most proximate protein environment that is directly involved in a chemical reaction, but ignore effects originating from the more distant protein environment. But even with these abstract representations of enzyme systems, fairly accurate predictions for specific metabolic reactions are possible 81 .
As MD simulations and QM methods deliver complementary information, it comes as no surprise that the combination of both approaches, referred to as quantum mechanical/molecular mechanical (QM/MM) methods 82 , has become a key technology for investigating enzyme reactions 61, 83 . The idea of the QM/MM hybrid approach is to tackle large systems by describing the region where a chemical reaction takes place by a QM method while accounting for the effects of the environment by MM methods. QM/MM methods have been used extensively for investigating the catalytic cycle of metabolic enzymes -primarily that of CYPs 61, 83 , but also of other enzymes such as epoxide hydrolase 84 and glutathione Stransferases 85, 86 . Reaction intermediates can be unstable with very short lifetimes, which makes them extremely challenging to observe with experimental approaches. Knowing their chemical structure is of immediate relevance to drug discovery, as it allows the rational design of molecules with specific binding properties (in particu lar, substrates or inhibitors). This is an area of research in which QM/MM methods can be effective.
A new direction to the QM calculation of full proteins is being explored by utilizing fragmentation methods such as divide andconquer or fragment molecular orbital theory (FMO) 87 , in which the protein is split into terminally capped amino acid fragments that are calculated locally and an overall energy is extracted from their pair interaction energies. Specifically designed GPUbased algorithms such as TeraChem 88 even allow for QM/MD simulations of full proteins in an MM solvent environment.
Calculating molecular flexibility and/or reactivity is not a trivial task, and it is important to note that such models depict one specific protein-ligand interaction or enzyme mechanism only. They are also com putationally fairly expensive, which is a fur ther complication in the implementation of such methods in drug discovery workflows. Fast QSAR methods have therefore been pre ferred in an attempt to incorporate reactivity implicitly through chemical descriptors 89, 90 . These are also generally confined to a specific type of metabolic reaction. Machine learning methods such as support vector machines (SVMs), artificial neural networks (ANNs) and random forests, however, are able to encode a whole range of different metabolic reactions, which is one of the main reasons for the popularity of these methods. The types of chemical descriptors used for encod ing sites of metabolism, their numbers and Component 7: metabolic networks/systems biology. Comprehensive models (simulators) of drug metabolism require the ability to correctly predict a whole cascade of events and properties of the system to allow the estimation of biological effects. This would involve accurate knowledge and prediction of the following: the concentrations and distribution of the drug; metabolic liabilities (sites of metabolism); the chemical structure of metabolites; interactions with pharma cologically and toxicologically relevant biomolecules; reaction rates; and tissue con centration and localization of enzymes and cofactors.
Although prediction of likely metabo lites is feasible, it is challenging to ascertain their pharmacological and toxicological relevance in the context of the biological system. Target prediction tools allow the identification of likely ligand-protein inter actions and the possible extrapolation of the contribution of these interactions to the pre diction of phenotypic effects using QSAR techniques. However, pharmacological effects are strongly linked to reaction rates and metabolite concentrations in specific tissues, which themselves are influenced by many factors, including the activity of trans porters. Possibly, these will only be reliably estimated if binding, ligand recognition and unbinding processes (pharmacodynamics) are understood at an atomic level of detail. Metabolic rates are specific to an enzyme and a substrate. Regardless of the structural or chemical significance of changes to sub strates, these can have a huge impact on the binding and unbinding processes (which are typically not included in algorithms to predict sites of metabolism and metabolites), and consequently, on metabolic rates 93 . Chemical modifications to one part of a molecule to increase its metabolic stability may in fact lead to metabolic switching, resulting in the expedited biotransformation at another position in the molecule. As a consequence, prediction of metabolic rates, if possible at all, is only feasible within an extremely narrow and welldefined chemi cal space 93 . Even if metabolic rates could be obtained, it is still a far cry from being able to estimate the effects of metabolites on a biological system, in particular as metabolic processes and biological responses can be highly specific to the individual 13 .
Integrated computational approaches.
Integrated computational approaches com bine a variety of data sources, models and algorithms in order to boost applicability, information content, significance and 43, 94 but a lot to gain by their combination. The targeted use of consensus approaches and composite modelling workflows represents further established strategies for improving the accuracy and significance of predictions -for example, for the task of bioactivity profiling 95, 96 . Pathway information and network analysis algorithms have been successfully integrated for predicting the PK/PD proper ties of drug molecules 46, 47 . Integration of data types and algorithms has also become a major driver of tools for regioselectivity and metabolite prediction. For example, knowledgebased systems use physico chemical property estimators and quality control quantum chemical methods to flag potentially toxic metabolites and reduce falsepositives rates. The latter has also been addressed by implementing docking as a postfiltering tool for generated metabolites 97 . MetaSite uses MIFs derived from the protein structure, combined with a fingerprintbased algorithm (fast docking surrogate method) and a quantum chemical approach (reactivity estimator). The impor tance of including reactivity, steric accessi bility and pharmacophoric constraints has been studied in detail for SMARTCyp 80, 98, 99 , but in fact most statistical and machine learning approaches make use of descriptors that encode these components.
Integrating experiment and computation A broad portfolio of experimental and theoretical methods for studying metabo lism at different levels of sophistication are now available. It is important to realize that when used independently, any of these approaches illuminate only specific aspects of drug metabolism and ignore most of the others. By contrast, the combination of vari ous experimental and theoretical approaches will generate a fairly complete picture of a compound's metabolic fate.
It might be assumed that the synergies created by the integration of both domains have long been harnessed by the pharmaceu tical industry, but in fact it seems that there is still some way to go to reach this point. The reasons for this situation are manifold: limited resources, costs of process restruc turing, organizational structures, timelines for learning cycles, diverging (and in part incompatible) schools of thought, and the limitations of current methods. A key prob lem is the open availability of relevant and diverse data, which are often kept as trade secrets in pharmaceutical companies and contract research organizations. Sharing these data is often impossible owing to intellectual property constraints. However, solving this problem will provide data related to a broader chemical space and thereby increase the applicability domain of computational prediction models.
Departments for computational and experimental research in drug metabolism are traditionally operated as 'silos' . Scientists of both areas have different backgrounds, use distinct terminologies, and are focused on applying their acquired expertise. Depending on the organizational setup of research organizations or projects, the level of integration of drug metabolism research varies greatly. Computational tools may be used by experts in drug metabolism and/or by computational or medicinal chemists. The latter tend to focus on SAR and syn thesis. Computational chemists may not have expert knowledge in pharmacokinetics, and sophisticated theoretical methods may not necessarily be within the comfort zone of specialists in drug metabolism. Close interplay of the different disciplines is therefore of utmost importance to tackle the problem of metabolism prediction. Efficient communication allows the development of appropriate models based on inhouse data to guide metabolic optimization. Early access to data on microsomal or hepatocyte stability is advantageous. A recent example for the successful liaison of experimental and theoretical approaches is the optimiza tion of the metabolic stability of mineralo corticoid receptor antagonists reported in BOX 2. But there is room for improvement, in particular with respect to modelling CYP induction, the rate and extent of metabolic reactions, and the prediction of phase II metabolism.
Conclusions and future directions
A plethora of powerful in vitro assay and analytical technologies are at our disposal, allowing us -in principle -to obtain a fairly complete and accurate picture of metabolic processes. Although it is likely that robust and costeffective metabolite generating systems such as hepatic micro somes will continue to provide a solid bedrock for metabolite generation, the development of socalled 3D bioreactor ('organ on a chip') technology is a rapidly developing field. These systems provide a much more 'in vivolike environment' for cells, which can be maintained for long periods while being exposed to drugs in order to assess metabolism and toxic ity [100] [101] [102] . If, as seems likely, such bioreactors (which are not limited to hepatocytes) can be made into a robust and easily deployed technology, this will represent a major advance for in vitro techniques.
Analytical techniques for drug metabo lite detection and identification are likely to remain focused on the use of MSbased technologies of everincreasing levels of sophistication and sensitivity for the fore seeable future. The development of robust miniaturized separation systems will further drive down the sample requirements 103 . Another promising development is the application of ion mobility spectrometry (IMS), which can enhance metabolite sepa ration and, through additional characteriza tion capability, improve the identification of sites of metabolism. The approach is based on separating isomeric species depending on differences in their IMS drift times, which are linearly proportional to the collision crosssection reflecting physical size and shape 104, 105 . Fundamental progress in the prediction of sites of metabolism and metabolites would result from improve ments in the reporting of additional metadata on the origin (tissues, genomes, experimental conditions, and so on) of samples, complete identification of major and minor products, improved experimen tal and statistical software tools for the normalization of mass spectral data, inte gration with transport phenomena and experimental data on the concentrations and rates of reaction.
Rapid advances can also be expected in the development of new animal models, either based on the engraftment of human cells into animals such as those seen in the 'chimeric humanized' mice, or animals that are genetically modified to contain human drugmetabolizing enzymes and transporters. These models can be expected to provide much more accurate predictions of the metabolic and pharmacokinetic properties of candidate drugs in humans 10, 11 , but they raise ethical issues.
Experimental approaches to investigate metabolism come with substantial demands in technical resources and human expertise. This is where computational chemistry can introduce a big leap forward in metabo lism research. Computational prediction of drug metabolism is still a young field of research, but in silico methods not only have Nature Reviews | Drug Discovery Major predicted SoM Minor predicted SoM MetID SoM the potential to guide or (partially) replace experimental efforts but they may also be the method of choice to investigate catalytic processes and highly reactive species. The most obvious synergy to be gained from the combination of both domains is from the coupling of software and spec troscopic instruments for more efficient metabolite identification and characteriza tion. Manufacturers of mass spectrometers are vigorously pursuing this approach.
Today, drug metabolism is typically addressed in the industrial setting rather than in academia, with the consequence that software and data are generally withheld and not available to the scientific community at large. However, the tide seems to be turning, and the availability of data coupled with new algorithmic approaches and open source software makes these methods more accessi ble to the scientific community. Data on the sites and products of metabolism, metabo lite concentrations and tissue locations of metabolizing enzymes are being collected and incorporated into various databases that address different aspects of metabolism, including drug and agrochemical metabo lism in a variety of species of plants and animals. The information stored ranges from data that are semantically rich to numerical data on the concentrations and locations of metabolites. Annotated meta bolic pathways and data on transporters complement this picture.
Metabolism is an example of an emergent process, and the complexity of the system is influenced by many extraneous and individual factors. Current computational approaches take little account of these and other factors, including transporters, proper consideration of metabolizing enzymes other than CYPs, environmental factors, and in particular the concentrations, meta bolic networks and rates of metabolism of metabolizing enzymes. Substantial progress is being made in gathering data for PK/PD modelling, and this will have a significant effect on the prediction of not only the metabolites that are present but also their concentrations and flux over time. In addi tion, the emerging field of metabonomics attempts to connect the metabolic state of an individual or population to phenotypic measures. This covers the whole gamut of metabolic research, from instrument design and measurement protocols to machine learning and clinical prediction. There is enormous potential in this area to combine all the experimental and theoretical methods to improve patient stratification and clinical outcomes.
Box 2 | Combination of experimental and theoretical approaches: a case study
An example of the fruitful combination of experimental and computational approaches to optimize metabolic compound stability in a pharmaceutical industry setting is provided by the work on a series of potent and selective non-steroidal mineralocorticoid receptor antagonists from a lead optimization project at Bayer HealthCare 123 . As metabolite identification (MetID) assays are limited in throughput, most of the optimization of metabolic properties was carried out via in vitro and in vivo stability assays combined with sites of metabolism (SoM) prediction with the Bayer in-house software CypScore 89 . In addition, in silico prediction allowed the profiling of alternative designs before synthesis. In the course of the project, hundreds of compounds and metabolites were predicted in silico, whereas only a small amount of MetID experiments could be performed.
A mineralocorticoid receptor antagonist (compound 1 in the figure) showed low metabolic stability in hepatocytes, with an F max (percentage of compound remaining) of 21% and also a high blood clearance (CL) in rats of 4.2 l per (h × kg). Oxidation of the 5-position (or 6-position) of the indole and two-step oxidation of the methyl group, leading first to the alcohol and then to the acid, were identified as the main metabolites via MetID assay experiments in human and rat liver microsomes. CypScore SoM predictions for compound 1 and the (not synthesized) metabolite 1-MET were in accordance with the experiment, but for 1-MET an additional weaker SoM was predicted at the carbon in the α-position to the cyano group. There was no experimental in-house evidence for such a metabolic reaction.
In accordance with the target structure-activity relationship (SAR), the methyl group was replaced with a nitrile in compound 2, which resulted in an increase in stability for rat hepatocytes, and an increase in F max to 34%, but not as much as expected. The major SoM was now the 5-position (or 6-position) of the indole, but again accompanied by the weaker predicted SoM at the α-carbon of compound 2, which was now also identified via MetID. Based on target fit and SoM prediction, the chain length was successfully reduced by one carbon, leading to compound 3. This increased the F max value to 63%. Further metabolic stabilization was consistently achieved by introducing derivatives with fluorination in the 5-position.
The metabolically labile methyl group in compound 1 was also replaced by various other substituents of different size, hydrophobicity and polarity. Several active sulfonamides were prepared that turned out to reduce the liability of the aromatic fragment, as exemplified by the low-clearance compound 4 with an F max of 75% and rat plasma clearance of 1.4 l per (h × kg).
This example shows the successful combination of various in vitro and in vivo experiments with in silico models to optimize the metabolic stability and, in parallel, the target activity of a compound series.
We will continue to see substantial gains in computational power, driven by GPU and cloud technology, increasingly efficient algo rithms, and advances in parallel computing. This will open up many new avenues for the development and application of highly accurate methods for the simulation of bio molecules and, indeed, whole biosystems.
For experimental and theoretical approaches alike, human expertise remains an important ingredient. The broad range of disciplines involved at the cutting edge of predictive drug metabolism is impressive. It draws on chemistry (physical, organic synthetic, analytical and medicinal chem istry), biology (biochemistry, enzymology, genetics and epigenetics), pharmacology (molecular pharmacology, clinical pharma cology, pharmacokinetics, toxicology and therapeutics) and computational components (software development, quantum chemistry, simulations, statistics and machine learning). For all of these experimental and theoretical domains of research, there is no technology available to date that is superior in all relevant scenarios. Bringing experimentalists and theoretical scientists closer together will result in progress. Ideally, a feedback loop of experiment, design and testing would greatly improve predictive models, as much of the present work has concentrated on retrospective analysis. In the future, closer collaboration is needed to further develop these models. Owing to the central role of metabolism in biology and the requirement that predictive models be incorporated into a wide variety of research and development programmes (for example, drug discovery, environmental science, clinical phenotyping and pesticide development), substantial resources will be applied and progress in understanding and in generating predictive models will continue.
